Alanine News and Research RSS Feed - Alanine News and Research

'Simple' model predicts PegIFN response in chronic HBV

'Simple' model predicts PegIFN response in chronic HBV

Chinese researchers have developed a scoring system based on hepatitis B virus-related clinical parameters to predict response to pegylated-interferon in chronic HBV patients. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Zinbryta gets FDA approval for treating adults with relapsing forms of MS

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly. [More]
WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Serum marker may flag liver fibrosis in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers. [More]
GLP-1 receptor agonist may benefit high-risk diabetes

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes. [More]
Dynamic HBsAg measurements predict HBV inactivity

Dynamic HBsAg measurements predict HBV inactivity

In patients with hepatitis B e antigen-negative chronic hepatitis B virus infection, repeated measurement of hepatitis B surface antigen during long-term follow-up can help identify those with inactive virus, suggests a chart review. [More]
HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers. [More]
Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Adding coffee to the diet of people with non-alcoholic fatty liver disease (NAFLD) could help reverse the condition, according to a new study conducted in mice presented at The International Liver Congress 2016 in Barcelona, Spain. [More]
Real-world data confirm TDF efficacy for HBV

Real-world data confirm TDF efficacy for HBV

Treatment with tenofovir disoproxil fumarate elicits sustained virological responses and exhibits a favourable safety profile in a diverse population of patients with chronic hepatitis B virus infection, shows a French routine clinical practice study. [More]
Combining medications may increase HBsAg loss in HBV patients

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial. [More]
Two-drug combination improves progression-free survival in patients with advanced melanoma

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial. [More]
New study finds link between maternal protein deficiency during pregnancy and metabolic diseases in offspring

New study finds link between maternal protein deficiency during pregnancy and metabolic diseases in offspring

A new study has uncovered the genetic processes that link insufficient protein consumption during pregnancy with the development of muscle problems in mothers and their male offspring. [More]
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. [More]
Inhibiting key protein involved in glucose production may help in treating type 2 diabetes

Inhibiting key protein involved in glucose production may help in treating type 2 diabetes

Some treatments for type 2 diabetes make the body more sensitive to insulin, the hormone that lowers blood sugar. But new research at Washington University School of Medicine in St. Louis suggests a different strategy: slowing the production of glucose in the liver. [More]
Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). [More]
Genotype A HBV mapped in acute, chronic Japanese patients

Genotype A HBV mapped in acute, chronic Japanese patients

Not only is genotype A the most common genotype among Japanese patients with acute hepatitis B virus infection, but its prevalence is spreading among young adults with chronic HBV infection, shows a nationwide study. [More]

Hepatic ALT flares linked to HBsAg clearance

Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers. [More]
Advertisement
Advertisement